Third-Party Oversight Of Device Changes Urged In Formal Complaint
This article was originally published in The Gray Sheet
FDA should amend its policy on device modifications to require their review by an independent third party, or the agency itself, prior to marketing, according to a Jan. 14 formal complaint
You may also be interested in...
Boston Scientific may opt to restart production of its original Rotablator atherectomy system following the Aug. 6 recall of the next-generation RotaLink Plus, the company reported at a same-day teleconference.
The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.
No device-related warning letters were released by the US FDA the week of 26 January.